Insider Selling: Paul Mahon Sells 6,000 Shares of United Therapeutics Corp. Stock (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) EVP Paul Mahon unloaded 6,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $84.38, for a total value of $506,280.00. Following the completion of the sale, the executive vice president now directly owns 34,490 shares in the company, valued at approximately $2,910,266. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.96% on Friday, hitting $85.48. 547,741 shares of the company’s stock traded hands. United Therapeutics Corp. has a 52-week low of $44.51 and a 52-week high of $85.92. The stock has a 50-day moving average of $76.23 and a 200-day moving average of $68.75. The company has a market cap of $4.267 billion and a P/E ratio of 14.60.
United Therapeutics Corp. (NASDAQ:UTHR) last released its earnings data on Thursday, July 25th. The company reported $1.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter in the prior year, the company posted $1.34 earnings per share. The company’s quarterly revenue was up 24.4% on a year-over-year basis.
A number of research firms have recently commented on UTHR. Analysts at Goldman Sachs Group Inc. raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $55.00 to $56.00 in a research note to investors on Wednesday, September 18th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics Corp. (NASDAQ:UTHR) in a research note to investors on Thursday, September 12th. They now have a $81.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $64.20.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.